Cancer Chemoprevention: What Have we Learned?

被引:0
|
作者
Yang C.S. [1 ]
Wang H. [1 ]
Dan V. [1 ]
Filippo S.S. [1 ]
机构
[1] Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 164 Frelinghuysen Road, Piscataway, 08854-8020, NJ
关键词
Aspirin; Cancer chemoprevention; Nutrients; Polyphenols; Tamoxifen; Tocopherols;
D O I
10.1007/s40495-017-0108-z
中图分类号
学科分类号
摘要
Cancer is a major disease worldwide and different approaches are needed to reduce its risk. Previous laboratory studies suggested that cancer can be prevented by many naturally occurring and synthetic chemicals. In human cancer prevention studies, however, most of the successful examples are the repurposing of existing drugs, such as tamoxifen and aspirin. Epidemiological studies have established associations between certain dietary patterns or nutrient insufficiencies with elevated cancer risk. Laboratory research has also shown impressive results on the cancer preventive activities of constituents from food and beverages. However, such cancer preventive activities have not been demonstrated in many human intervention trials. This article reviews the advances in this field and discusses the reasons for the discrepancies between laboratory studies and human trials. Lessons learned for cancer prevention research in the past decades will be illustrated using studies with β-carotene, vitamin E, green tea polyphenols, tamoxifen, and aspirin as examples. In future studies, more interdisciplinary collaboration in the integration of laboratory and human studies are needed to advance the field of cancer chemoprevention. © 2017, Springer International Publishing AG.
引用
下载
收藏
页码:409 / 422
页数:13
相关论文
共 50 条
  • [1] Chemoprevention of prostate cancer: what have we learned?
    Hamilton, Robert J.
    TRENDS IN UROLOGY & MENS HEALTH, 2014, 5 (05) : 25 - 29
  • [2] CHEMOPREVENTION: RANDOMIZED STUDIES & WHAT HAVE WE LEARNED
    Hong, Waun K.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S208 - S208
  • [3] Colorectal Chemoprevention trials; What have we learned? What's next?
    Baron, J
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1373S - 1373S
  • [4] Chemoprevention in colorectal cancer - where we stand and what we have learned from twenty years' experience
    Boghossian, Shahe
    Hawash, Ahmed
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2012, 10 (01): : 43 - 52
  • [5] Cancer clusters: what have we learned?
    Stewart, B. W.
    INTERNAL MEDICINE JOURNAL, 2013, 43 (01) : 5 - 6
  • [6] Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far?
    Machado de Melo, Fabiana Henriques
    Oliveira, Julia Salles
    Bressani Sartorelli, Viviani Olivastro
    Montor, Wagner Ricardo
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [7] Why phase II trials in cervical chemoprevention are negative: what have we learned?
    Michele Follen
    Anne-Thérèse Vlastos
    Frank L. Meyskens
    E. Neely Atkinson
    David Schottenfeld
    Cancer Causes & Control, 2002, 13 : 855 - 873
  • [8] Why phase II trials in cervical chemoprevention are negative: what have we learned?
    Follen, M
    Vlastos, AT
    Meyskens, FL
    Atkinson, EN
    Schottenfeld, D
    CANCER CAUSES & CONTROL, 2002, 13 (09) : 855 - 873
  • [9] Lymphopenia in Esophageal Cancer: What Have We Learned?
    Wang, Jia-Lin
    Ma, Rong
    Kong, Wei
    Zhao, Ren
    Wang, Yan-Yang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] DNA Sequencing of Cancer: What Have We Learned?
    Chmielecki, Juliann
    Meyerson, Matthew
    ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 : 63 - 79